参考文献/References:
[1]Amer MH.Gene therapy for cancer:present status and future perspective[J].Mol Cell Ther，2014(2):27. [2]Navarro SA,Carrillo E,Grinan-Lison C,et al.Cancer suicide gene therapy:a patent review[J]. Expert Opin Ther Pat,2016,26(9):1095-1104. [3]Shao D,Li J,Xiao X,et al.Real-time visualizing and tracing of HSV-TK/GCV suicide gene therapy by near-Infrared fluorescent quantum dots[J].ASC Appl Mater Interfaces,2014,6(14):11082-11090. [4]Lee M,Kim YS,Lee K,et al.Novel Semi-Replicative Retroviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblastoma Models[J]. Cancers,2019,11(8):E1090. [5]Gwak SJ,Lee JS.Suicide Gene Therapy By Amphiphilic Copolymer Nanocarrier for Spinal Cord Tumor[J].Nanomaterials,2019,9(573):44-58. [6]Gujrati M,Lu ZR.TargetedSystemic Delivery of Therapeutic siRNA[M]//Gene Therapy of Cancer.2014. [7]Sato Y,Murase K,Kato J,et al.Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone[J].Nat Biotechnol,2008,26(4):431-442. [8]Pang W,Zhai Mi,Wang Y,et al.Long noncoding RNA SNHG16 silencing inhibits the aggressiveness of gastric cancer via upregulation of microRNA-628-3p and consequent decrease of NRP1[J].Cancer Manag Res,2019(11):7263-7227. [9]Singh A,Trivedi P,Jain NK.Advances in siRNA delivery in cancer therapy[J].Artif Cells Nanomed Biotechnol,2018,46(2):274-283. [10]Davis ME.The first targeted delivery of siRNA in humans via a selfassembling,cyclodextrin polymer-based nanoparticle:from concept to clinic[J].Mol Pharm,2009,6(3):659-668. [11]Tabernero J,Shapiro GI,LoRusso PM,et al.First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement[J]. Cancer Discov,2013,3(4):406-417. [12]Fung H,Gersson S.Viral insertion site detection and analysis in cancer gene therapy[M]// In Gene Therapy of Cancer(3rd edition).2014:35-46. [13]Perri F,Longo F,Giuliano M,et al.Epigenetic control of gene expression:Potential implications for cancer treatment[J].Crit Rev Oncol Hematol,2017(111):166-172. [14]Nervi C,De Marinis E,Codacci-Pisanelli G,et al.Epigenetic treatment of solid tumours:a review of clinical trials[J].Clin Epigenet,2015,7(12):127. [15]Deng YJ,Zhao YM,Cheng F,et al.The latest research progress of tumor suppressor gene NDRG2[J].Journal Of Modern Oncology,2014,4(72):962-965. [16]Day A,Verma CS,Lane DP.Modulation of p53 degradation as a therapeutic approach[J].Cancer,2008,98(1):4-8. [17]Sanz G,Singh M,Peuget S.Inhibition of p53 inhibitors:progress,challenges and perspectives. [J].J Mol Cell Biol,2019,11(7):586-599. [18]Collinet P,Vereecque R,Sabban F,et al.In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice[J].J Obstet Gynaecol Res,2006,32(5):449-453. [19]Song C,Lu P,Sun G,et al.miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis[J].Biochem Biophys Res Commun,2017,482(1):22-27. [20]Xu J,Su C,Zhao F,et al.Paclitaxel promotes lung cancer cell apoptosis via MEG3-P53 pathway activation[J].Biochem Biophys Res Commun,2018,504(1):123-128. [21]Liu Q,Sui R,Li R,et al.Biological characteristics of Taxol-resistant ovarian cancer cells and reversal of Taxol resistance by adenovirus expressing p53[J].Mol Med Rep,2015,11(2):1292-1297. [22]Lin JT,Chen H,Wang D,et al.Nuclear-targeted p53 and DOX co-delivery of chitosan derivatives for cancer therapy in vitro and in vivo[J].Elsevier,2019,183(110440):114-137. [23]Kim DH,Suh J,Surh YJ,et al.Regulation of the tumor suppressor PTEN by natural anticancer compounds[J].Ann N Y Acad Sci,2017,1401(1):136-149. [24]Wu H,Wang K,Liu W,et al.Recombinant adenovirus-mediated overexpression of PTEN and KRT 10 improves cisplatin resistance of ovarian cancer in vitro and in vivo[J].Genet Mol Res,2015,14(2):6591-6597. [25]Wu H,Wang S,Weng D,et al.Reversal of the malignant phenotype of ovarian cancer A2780 cells through transfection with wild-type PTEN gene[J].Cancer Lett,2008,(271):205-214. [26]Jung SH,Hwang HJ,Kang D,et al.mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53[J].Oncogene,2019,38(10):1639-1650. [27]Reardon DA,Wucherpfennig KW,Freeman G,et al.An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma[J].Expert Rev Vaccines,2013,12(6):597-615. [28]Wolff JA,Budker V.The mechanism of naked DNA uptake and expression[J].Adv Genet,2005(54):3-20. [29]Lopes A,Vandermeulen G,Préat V.Cancer DNA vaccines:current preclinical and clinical developments and future perspectives[J].J Exp Clin Cancer Res,2019,38(1):146. [30]Muniyan S,Chaturvedi NK,Dwyer JG,et al.Human prostatic acid phosphatase:structure,function and regulation[J].Int J Mol Sci,2013,14(5):10438-64. [31]Hong IS.Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types[J].Exp Mol Med,2016,48(7):e242. [32]Staff C,Mozaffari F,Haller BK,et al.A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients[J].Vaccine,2011,29(39): 6817-6822. [33]Rosa DS,Ribeiro SP,Almeida RR,et al.A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional,long-lived CD4+ and CD8+ T cell responses[J].PLoS One,2011,6(2):e16921. [34]Lambertini M,Pondé NF,Solinas C,et al.Adjuvant trastuzumab:a 10-year overview of its benefit[J].Expert Rev Anticancer Ther,2017,17(1):61-74. [35]Salles G,Barrett M,Foà R,et al.Rituximab in B-Cell Hematologic Malignancies:A Review of 20 Years of Clinical Experience[J].Adv Ther,2017,24(10):2232-2273. [36]Park T,Choi CJ,Choi Y,et al.Cost-effectiveness of cetuximab for colorectal cancer[J].Expert Rev Pharmacoecon Outcomes Res,2016,16(6):667-677. [37]Diaz RJ,Ali S,Qadir MG,et al.The role of bevacizumab in the treatment of glioblastoma[J]. J Neurooncol,2017,133(3):455-467. [38]Yaghoubi S,Karimi MH,Lotfinia M,et al.Potential drugs used in the antibody-drug conjugate (ADC)architecture for cancer therapy[J].J Cell Physiol,2019(3):1-34. [39]Hinrichs CS,Stevanovic S,Draper L,et al.HPV-targeted tumor-infiltrating lymphocytes for cervical cancer[J].Clin Oncol,2014,32(18):233-245. [40]Guzik K,Zak KM,Grudnik P,et al.Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1(PD-1/PD-L1)Interaction via Transiently Induced Protein States and Dimerization of PD-L1[J].J Med Chem,2017,60(13):5857-5867. [41]Ahmed SR,Petersen E,Patel R.Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma[J].Expert Rev Clin Pharmacol,2019(19):1-5. [42]Lin X,Khalid S,Qureshi MZ,et al.VEGF mediated signaling in oral cancer[J].Cell Mol Biol, 2016,62(14):64-68. [43]Zhang Y,Zou JY,Wang Z,et al.Fruquintinib:a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer[J].Cancer Manag Res,2019,11(2019):7787-7803. [44]Sopo M,Anttila M,Sallinen H,et al.Antiangiogenic gene therapy with soluble VEGF-receptors -1,-2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma[J].Cancer,2012(131):2394-2401. [45]Tuppurainen L,Sallinen H,Kokki E,et al.Preclinical safety,toxicology,and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer[J].Hum Gene Ther Clin Dev,2013(24):29-37.
相似文献/References:
[1]陈青娟.当癌症汹涌来袭 我们该如何应对？[J].医学信息,2018,31(03):1.[doi:10.3969/j.issn.1006-1959.2018.03.001]
[2]田新学,孙倩倩,赵可雷,等.癌因性疲乏相关治疗研究进展[J].医学信息,2018,31(11):46.[doi:10.3969/j.issn.1006-1959.2018.11.015]
TIAN Xin-xue,SUN Qian-qian,ZHAO Ke-lei,et al.Advances in Researches Related to Cancer-related Fatigue[J].Medical Information,2018,31(03):46.[doi:10.3969/j.issn.1006-1959.2018.11.015]
[3]刘 英,杭 菲,李晨曦,等.集束化护理对癌症患者的临床应用进展[J].医学信息,2019,32(02):55.[doi:10.3969/j.issn.1006-1959.2019.02.018]
LIU Ying,HANG Fei,LI Chen-xi,et al.Progress in Clinical Application of Cluster Therapy for Cancer Patients[J].Medical Information,2019,32(03):55.[doi:10.3969/j.issn.1006-1959.2019.02.018]
[4]林夏妃,吴海霞,随燕芳,等.2009~2018年癌症康复研究的CiteSpace科学知识图谱可视化分析[J].医学信息,2020,33(02):1.[doi:10.3969/j.issn.1006-1959.2020.02.001]
LIN Xia-fei,WU Hai-xia,SUI Yan-fang,et al.Visual Analysis of CiteSpace Scientific Knowledge Map for Cancer Rehabilitation Research from 2009 to 2018[J].Medical Information,2020,33(03):1.[doi:10.3969/j.issn.1006-1959.2020.02.001]
[5]王黎平,吕显贵,何雪冬,等.芳香疗法对癌症患者焦虑抑郁情绪影响的Meta分析[J].医学信息,2020,33(17):58.[doi:10.3969/j.issn.1006-1959.2020.17.017]
WANG Li-ping,LYU Xian-gui,HE Xue-dong,et al.Meta-analysis of the Effects of Aromatherapy on Anxiety and Depression in Cancer Patients[J].Medical Information,2020,33(03):58.[doi:10.3969/j.issn.1006-1959.2020.17.017]
[6]王永妮,常雅楠,赵彩萍,等.基于CiteSpace的国内外疾病获益感研究的可视化分析[J].医学信息,2023,36(16):47.[doi:10.3969/j.issn.1006-1959.2023.16.008]
WANG Yong-ni,CHANG Ya-nan,ZHAO Cai-ping,et al.Visual Analysis of Benefit Finding Research at Home and Abroad Based on CiteSpace[J].Medical Information,2023,36(03):47.[doi:10.3969/j.issn.1006-1959.2023.16.008]
[7]孙佳一,赵志芳.基于CiteSpace癌症患者照顾者负担研究热点的可视化分析[J].医学信息,2024,37(05):50.[doi:10.3969/j.issn.1006-1959.2024.05.008]
SUN Jia-yi,ZHAO Zhi-fang.Visualization Analysis of Research Hotspots of Caregiver Burden of Cancer Patients Based on CiteSpace[J].Medical Information,2024,37(03):50.[doi:10.3969/j.issn.1006-1959.2024.05.008]
[8]刘杉杉,张小燕,李红云.基于移动健康的信息支持在出院后农村老年癌症患者中的应用[J].医学信息,2024,37(07):143.[doi:10.3969/j.issn.1006-1959.2024.07.029]
LIU Shan-shan,ZHANG Xiao-yan,LI Hong-yun.Application of Mobile Health-based Information Support Among Rural Elderly Cancer Patients After Discharge[J].Medical Information,2024,37(03):143.[doi:10.3969/j.issn.1006-1959.2024.07.029]